Ludwig Enterprises, Inc. Liquidation Value

LUDG Medical Laboratories

Cash & Equivalents

$0
As of 2025-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $0
Total Obligations: -$4.64M
$-4.64M
Per share: $-0.03
Period: 2025-12-31
incomplete 3 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Finance Lease Liability: not reported
  • Operating Lease Liability: not reported

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $0
AR: $106,000
Total Obligations: -$4.64M
$-4.53M
Per share: $-0.03
Period: 2025-12-31
incomplete 3 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Finance Lease Liability: not reported
  • Operating Lease Liability: not reported

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $0
AR: $106,000
Inventory: $4,529
Total Obligations: -$4.64M
$-4.53M
Per share: $-0.03
Period: 2025-12-31
incomplete 3 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Finance Lease Liability: not reported
  • Operating Lease Liability: not reported

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-4.64M$-0.03
Liquid Liquidation Value$-4.53M$-0.03
Operating Liquidation Value$-4.53M$-0.03

Key Components (as of 2025-12-31)

Data as of 2025-12-31 from 10-K filed 2026-03-16. View on SEC EDGAR →

Cash & Equivalents$0
Accounts Receivable$106,000
Inventory$4,529
Current Liabilities$4.64M
Long-term Debt (?)N/A
Op. Lease Liability (?)N/A
Finance Lease (?)N/A
Shares Outstanding162.6M

Explore all 99 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$0$106,000$4,529N/A$4.64MN/AN/AN/A
2025-09-30$3,317$106,000$4,529N/A$3.57MN/AN/AN/A
2025-06-30$142,474$104,000$3,048N/A$3.80MN/AN/AN/A
2025-03-31$16,571$102,000$3,048N/A$3.01MN/AN/AN/A
2024-12-31$217$100,000$3,048N/A$2.58M$628,708N/AN/A
2024-09-30$43,352N/AN/AN/A$2.47MN/AN/AN/A
2024-06-30$201,907N/AN/AN/A$2.26MN/AN/AN/A
2024-03-31$345,470N/AN/AN/A$2.00M$405,000N/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-K 2026-03-16 View
2025-09-30 10-Q 2025-11-12 View
2025-06-30 10-Q 2025-08-12 View
2025-03-31 10-Q 2025-05-15 View
2024-12-31 10-K 2025-03-31 View
2024-09-30 10-Q 2024-11-14 View
2024-06-30 10-Q 2024-08-13 View
2024-03-31 10-Q 2024-05-20 View

AI Insights

AI Insight·Generated 2026-05-06

Ludwig Enterprises, Inc. (LUDG) presents a deeply negative liquidation posture as of December 31, 2025. Total assets of $248K are overwhelmed by total liabilities of $4.64M, yielding a GAAP stockholders' deficit of -$4.39M. MFFAIS-computed liquidation values confirm: CLV -$4.64M, LLV -$4.53M, OLV -$4.53M. Under liquidation lens, asset recovery is negligible: cash is effectively zero (reported as a $1,252 bank overdraft, not a positive balance), inventory recovers at 60% of $4,529 (~$2.7K), prepaid expenses ($14.9K) recover at zero, notes receivable ($106K) are highly speculative given the counterparty is Marijuana Inc. (MAJI), a contingent-payment instrument that is already in default on a $100K promissory note due December 31, 2025. Deferred offering costs ($113K) recover at zero under liquidation. Intangibles ($9.2K) recover at zero. No PP&E disclosed. On the liability side, the full $4.64M stays at face value. The liability stack consists of: accounts payable and accrued liabilities ($791K), notes payable - net ($1.27M, 13 unsecured promissory notes extended to March 31, 2026), convertible notes payable ($1.17M, derivative-laden instruments with variable conversion features triggered on uplisting), a derivative liability ($535K, Level 3 Black-Scholes, bifurcated from convertible notes), related-party current liabilities ($55K), and a bank overdraft ($1.3K). Accrued executive compensation obligations (CFO $98K, CEO $161K, CSO $205K) are embedded within the $791K accrued liabilities line. The Purchaser Note receivable from Marijuana Inc. ($100K principal, 8% interest, due December 31, 2025) is explicitly noted as in default and is carried at face on the asset side — recovery under liquidation is highly uncertain and assigned near-zero value here. Convertible note face amount increased materially YoY: from $578K at 12/31/2024 to $1.17M at 12/31/2025, driven by $750K in new 2025 issuances with variable conversion features. A $953.6K derivative liability was recognized as debt discount on these instruments, fully amortized during the year ($796K amortization of debt discount), producing a $117K loss on extinguishment. The derivative liability net balance at year-end is $535K. The filing does not separately tag total accrued compensation liabilities as a distinct XBRL concept; those amounts appear embedded in AccountsPayableAndAccruedLiabilitiesCurrent and OtherAccruedLiabilitiesCurrentAndNoncurrent. A post-period settlement agreement (March 12, 2026) commits the company to pay former CEO Todd $275K in accrued salary plus $36.9K note principal plus interest, contingent on an uplisting — this contingent liability is not reflected on the December 31, 2025 balance sheet and is not separately XBRL-tagged. Change from prior filing (10-Q for period ended September 30, 2025): convertible notes payable and derivative liability are new year-end additions relative to the Q3 2025 interim period; the full-year 10-K crystallizes the liability stack. The company remains a pre-revenue entity with no operating cash generation capability.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...